A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during
 dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C
 infection
Inclusion Criteria:

 -  Chronically infected with Hepatitis C Virus (HCV) genotype 1

 -  Treatment naive or treatment non-responders or treatment intolerant; and not
 co-infected with HIV or Hepatitis B Virus

 -  HCV RNA viral load of ≥10*5 IU/mL

 -  BMI 18 to 35kg/m²

 Exclusion Criteria:

 -  Any significant acute or chronic medical illness which is not stable or is not
 controlled with medication and not consistent with Hepatitis C Virus infection

 -  HIV and/or HBV positive

 -  Major surgery within 4 weeks of study drug administration and any gastrointestinal
 surgery that could impact the absorption of study drug

 WOCBP will be enrolled as in-patient for 16 days